Carna Biosciences Inc

Carna Biosciences operates with a debt-to-equity ratio of 2.31 and a current ratio of 6.99, indicating a strong liquidity position despite a negative net cash position after subtracting total debt. The company holds 516,789,000 JPY in cash and equivalents, which is partially offset by 714,487,000 JPY in long-term debt. This capital structure suggests a reliance on equity and long-term debt to fund operations, with a high degree of leverage that could amplify losses during periods of declining revenue. The company's profitability metrics are weak, with a return on equity of -7.02% and a return on assets of -1.77%, both significantly below the industry median for biotechnology and medical research firms. These figures reflect a challenging operating environment, with a net loss of 2,171,470,000 JPY and an operating loss of 2,099,730,000 JPY in the latest reporting period. The gross profit margin of 67.0% is relatively strong, but this is insufficient to offset the high operating expenses. Carna Biosciences operates in two segments: Drug Development Support and Drug Development. The Drug Development Support segment generates revenue through the sale of protein kinase, assay development, and profiling and screening services. The Drug Development segment focuses on the research and development of kinase inhibitors and other drugs. However, the company does not disclose revenue by segment, making it difficult to assess the contribution of each business line to overall performance. The company's growth trajectory is uncertain, with no specific revenue growth projections provided in the outlook. The latest financial data shows a revenue of 579,057,000 JPY, but the operating cash flow is negative at -2,159,363,000 JPY, and the free cash flow is also negative at -2,180,750,000 JPY. These figures suggest that the company is not generating sufficient cash from operations to sustain its current level of investment and debt service. The risk assessment for Carna Biosciences indicates a medium liquidity risk and a low dilution risk. The key flag of negative net cash after subtracting total debt highlights the company's reliance on external financing to meet its obligations. The dilution risk is low, as the number of shares outstanding has not changed between basic and diluted shares. However, the company's negative operating and free cash flows could necessitate future equity or debt financing, which may lead to dilution if not managed carefully. Recent events and filings do not provide specific details on new product launches, partnerships, or regulatory approvals. The company's focus on drug development and support services is consistent with its long-term strategy, but the absence of recent positive developments or significant revenue growth suggests that the company is still in a development phase with limited commercial success.